Literature DB >> 26978714

Long-term follow-up after LeFort colpocleisis: patient satisfaction, regret rate, and pelvic symptoms.

Xiaochen Song1, Lan Zhu, Jing Ding, Tao Xu, Jinghe Lang.   

Abstract

OBJECTIVE: The aim of the study was to evaluate long-term patient satisfaction, regret rate, and pelvic symptoms in older women who underwent LeFort colpocleisis.
METHODS: A retrospective cohort study of women who underwent LeFort colpocleisis at least 3 years before was conducted. Records were reviewed for participant characteristics, comorbid conditions, and complications. The Patient Global Impression of Change (PGI-C) questionnaire and the Chinese version of the Pelvic Floor Distress Inventory-short form 20 (PFDI-20) were used to evaluate self-perceived quality of life. Regret was assessed by one additional question: "Do you regret choosing to have vaginal closure surgery for prolapse (Yes/No)?"
RESULTS: LeFort colpocleisis accounted for 7.3% (42/572) of all the prolapse surgeries. Thirty-five of the women (83.3%) who responded were considered for statistical evaluation. Twenty-nine (82.9%) had at least one comorbid condition. After a median 5-year (range 3-7) follow-up period, no woman had experienced prolapse recurrence requiring a second surgery. No woman regretted having had the surgery. The satisfaction rate was 94.3%, with postoperative overactive bladder syndrome accounting for one "neither satisfied nor dissatisfied" woman and vaginal hematoma for another. Pelvic symptoms improved significantly from baseline (PFDI-20, preoperative 60.5 ± 29.5) to postoperative (14.1 ± 20.0, P < 0.001).
CONCLUSIONS: After long-term follow-up, LeFort colpocleisis still had a high satisfaction rate, a low regret rate, and a positive impact on pelvic symptoms.

Entities:  

Mesh:

Year:  2016        PMID: 26978714     DOI: 10.1097/GME.0000000000000604

Source DB:  PubMed          Journal:  Menopause        ISSN: 1072-3714            Impact factor:   2.953


  8 in total

1.  LeFort colpocleisis: a step-by-step simulation video for Female Pelvic Surgeons.

Authors:  Andrey Petrikovets; Theresa Fisher; Christina Krudy; David Sheyn; Jeffrey Mangel; Sangeeta T Mahajan
Journal:  Int Urogynecol J       Date:  2017-12-26       Impact factor: 2.894

Review 2.  Enlightening the mechanisms of POP recurrence after LeFort colpocleisis. Case report and review.

Authors:  Themistoklis Mikos; Mariliz Chatzipanteli; Grigoris F Grimbizis; Basil C Tarlatzis
Journal:  Int Urogynecol J       Date:  2016-12-26       Impact factor: 2.894

Review 3.  How does colpocleisis for pelvic organ prolapse in older women affect quality of life, body image, and sexuality? A critical review of the literature.

Authors:  Laetitia Felder; Viola Heinzelmann-Schwarz; Tilemachos Kavvadias
Journal:  Womens Health (Lond)       Date:  2022 Jan-Dec

Review 4.  Colpocleisis as an obliterative surgery for pelvic organ prolapse: is it still a viable option in the twenty-first century? Narrative review.

Authors:  Magdalena Emilia Grzybowska; Konrad Futyma; Aida Kusiak; Dariusz Grzegorz Wydra
Journal:  Int Urogynecol J       Date:  2021-08-18       Impact factor: 1.932

5.  Surgical and quality of life outcomes after pelvic organ prolapse surgery in older postmenopausal women.

Authors:  Mohamed M Farghali; Abeer Abdelzaher; Ibrahim A Abdelazim
Journal:  Prz Menopauzalny       Date:  2021-03-15

6.  Psychometric Evaluation of the Chinese Version of the Decision Regret Scale.

Authors:  Richard Huan Xu; Ling Ming Zhou; Eliza Laiyi Wong; Dong Wang; Jing Hui Chang
Journal:  Front Psychol       Date:  2020-12-03

7.  Modified Lefort partial colpocleisis.

Authors:  Hongtao Lv; Fengnian Rong
Journal:  Int Urogynecol J       Date:  2020-10-01       Impact factor: 2.894

8.  Long-Term Clinical Outcomes, Recurrence, Satisfaction, and Regret After Total Colpocleisis With Concomitant Vaginal Hysterectomy: A Retrospective Single-Center Study.

Authors:  Meiqiu Lu; Wei Zeng; Rui Ju; Shasha Li; Xin Yang
Journal:  Female Pelvic Med Reconstr Surg       Date:  2021-04-01       Impact factor: 1.913

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.